Limit search to available items
Book Cover
E-book

Title Emerging drugs and targets for Parkinson's disease / edited by Ana Martinez and Carmen Gil
Published Cambridge : Royal Society of Chemistry, 2014
Online access available from:
Royal Society of Chemistry eBooks    View Resource Record  

Copies

Description 1 online resource
Series RSC drug discovery
RSC drug discovery series.
Contents Overview on Parkinson disease. Rational for pharmacological intervention; Dopaminergic pathway and L-Dopa treatments. Future challenges; COMT Inhibitors: present problems and relevance of the new ones; MAO inhibitors for PD (Safinamide); Dopamine agonist: present and future (Pardoprunox); Therapies for dopaminergic-induced dyskinesias in Parkinson disease. (Fipamizole); Beyond the dopamine receptor: regulation of protein phosphatases; Molecular chaperones as rational drug targets for Parkinson's disease therapeutics; Alpha-synuclein assembly as a therapeutic target of PD; Alpha-synuclein (alpha-syn) phosphorylating polo-like kinase 2 (PLK2) as target for PD; Hsp70 molecular chaperones and Parkinson's disease; Glutamate receptors as therapeutic targets for Parkinson's disease; Targeting adenosine A2A receptors in Parkinson's disease; Leucine-rich repeat kinase-2 as target for Parkinson's disease; Phosphodiesterase inhibitors for PD treatment; P2X7 purinergic receptor: role in neurological disorders; Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease; D3 dopamine receptor agonists: neuroprotection in Parkinson's disease; Antioxidants and PD; Tryptophan metabolism in Parkinson's disease; Grafted neural stem cell-derived dopaminergic neurons for PD Therapy; Gene therapy for Parkinson's disease; Carotid body autotransplantation in Parkinson disease;Neurotrophic factor therapy for Parkinson's disease
Summary Affecting over 1.5 million people across the world, Parkinson's disease is a progressive neurological condition characterized, in part, by the loss of dopaminergic neurons in the substantia nigra pars compacta. It affects 1.5% of the global population over 65 years of age. As life expectancy is increasing, over the next few years the number of patients with Parkinson's disease will grow exponentially. To date, there are no available treatments that are capable of curing Parkinson's disease, and the current goal of therapy, dopamine replacement strategies, is to reduce symptoms. After several years of disease progression, treatment is complicated by the onset of motor fluctuations and dyskinesias. This information reveals the great importance and social need of finding an effective therapeutic intervention for Parkinson's disease. This exemplary new book reviews some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets currently undergoing the validation process to try to reach the Parkinson's drug market in the next few years as potential disease modifying drugs. Providing up to date and comprehensive coverage, this book will be essential reading for researchers working in academia and industry in any aspect of medicinal chemistry or drug discovery
Notes Publisher supplied information
Subject Antiparkinsonian agents.
Drug development.
Parkinson's disease -- Chemotherapy.
Pharmaceutical chemistry.
Form Electronic book
Author Gil, Carmen (Gil Ayuso-Gontán)
Martínez, Ana.
ISBN 1849737355 (electronic bk.)
9781849737357 (electronic bk.)